RECRUITING

Bright Light Therapy on Sleep Health in Lung Cancer Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are: * Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients? * Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging. Participants will: * Receive bright light exposure or usual light exposure every day for 4 weeks * Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests * Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks * Keep a daily sleep log

Official Title

Bright Light Therapy to Reduce Sleep Disturbance and Biological Aging in Lung Cancer Patients

Quick Facts

Study Start:2025-06-09
Study Completion:2026-02-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07064395

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * \>=18 years of age
  2. * Stage Ib to IIIb primary lung cancer diagnosis
  3. * \>=2 months after completion of primary therapy, patient can continue to be on maintenance/immunotherapy
  4. * ECOG performance status is 0 or 1
  5. * Experience problematic sleep (scores of \>=8 on the Insomnia Severity Index)
  6. * Able to understand, speak, and read English
  7. * Sighted and mentally competent to consent
  1. * Pregnant women
  2. * Have metastatic cancer
  3. * on oxygen therapy
  4. * Current diagnosis of seasonal affective disorder or substance abuse
  5. * Engage in shift work or travel across \>3 time zones within 2 weeks prior to the study
  6. * Are currently being treated for sleep apnea, restless legs syndrome, or narcolepsy
  7. * Take prescribed sedative hypnotics or antipsychotics
  8. * Have eye conditions (glaucoma or retinal disease), problem triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents)
  9. * Participants with an Insomnia Severity Index \<8
  10. * Participants with cognitive impairment (sores of \<3 mini-cog test)

Contacts and Locations

Study Contact

Menghua Tao, PhD
CONTACT
313-590-9408
mtao1@hfhs.org

Study Locations (Sites)

Henry Ford Health System
Detroit, Michigan, 48202
United States

Collaborators and Investigators

Sponsor: Henry Ford Health System

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-09
Study Completion Date2026-02-28

Study Record Updates

Study Start Date2025-06-09
Study Completion Date2026-02-28

Terms related to this study

Keywords Provided by Researchers

  • bright light
  • intervention
  • biological age
  • sleep
  • lung cancer

Additional Relevant MeSH Terms

  • Lung Cancers